Saptalis Pharmaceuticals develops and manufactures specialty generic and innovative medicines using ANDA and 505(b)(2) regulatory pathways to create complex dosage forms. The company addresses the need for high-quality, affordable medications in niche therapeutic areas, improving patient access and quality of life.
Funding
$6.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many patients lack access to affordable, high-quality generic and innovative medicines, particularly in niche therapeutic areas and complex dosage forms. The development and manufacturing of these specialized medications can be challenging and costly, limiting their availability.
Solution
Saptalis Pharmaceuticals develops, manufactures, and commercializes specialty generic and innovative medicines using ANDA and 505(b)(2) regulatory pathways. The company focuses on creating complex dosage forms, including oral liquids and topical creams/ointments, to address unmet needs in niche therapeutic areas. Saptalis leverages its R&D expertise and cGMP manufacturing capabilities to provide cost-effective, high-quality medications. By focusing on specialized products and efficient development processes, Saptalis aims to improve patient access to essential medicines.
Target Audience
The primary customers are patients who require specialized medications in niche therapeutic areas, as well as healthcare providers seeking affordable and high-quality treatment options.
Features
- Specializes in developing and manufacturing oral liquid and topical cream/ointment products.
- Utilizes ANDA and 505(b)(2) regulatory pathways for efficient product approval.
- Employs cGMP manufacturing practices to ensure product quality and consistency.
- Offers a portfolio of niche generic and innovative specialty products.
- Provides a cost-effective and time-efficient product development process.